Congruent deterioration of complex and simple movements in patients with Huntington's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 68, 2004, Pages 97-104

  Saft, C ^a   Andrich, J ^a   Meisel, N M ^a   Przuntek, H ^a   Muller Th ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; MEMANTINE; PERPHENAZINE; PIPAMPERONE; RISPERIDONE; SULPIRIDE; TETRABENAZINE; TIAPRIDE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DETERIORATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FINGER; HAND MOVEMENT; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; LEFT HANDEDNESS; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PRIORITY JOURNAL; RIGHT HANDEDNESS; SCORING SYSTEM; TASK PERFORMANCE;

EID: 4544221197     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-0579-5_11     Document Type: Article

References (25)

1. Anonymous (1996) Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 11: 136-142
2. Benitez J, Fernandez E, Garcia RP, Robledo M, Ramos C, Yebenes J (1994) Trinucleotide (CAG) repeat expansion in chromosomes of Spanish patients with Huntington's disease. Hum Genet 94: 563-564
3. Brown RG, Marsden CD (1990) Cognitive function in Parkinson's disease: from description to theory. Trends Neurosci 13: 21-29
4. Carey LM, Abbott DF, Egan GF, Tochon-Danguy HJ, Donnan GA (2000) The functional neuroanatomy and long-term reproducibility of brain activation associated with a simple finger tapping task in older healthy volunteers: a serial PET study. Neuroimage 11: 124-144
5. Claus JJ, Mohr E (1996) Attentional deficits in Alzheimer's, Parkinson's, and Huntington's diseases. Acta Neurol Scand 93: 346-351
6. de Boo GM, Tibben A, Lanser JB, Jennekens-Schinkel A, Hermans J, Maat-Kievit A, Roos RA (1997) Early cognitive and motor symptoms in identified carriers of the gene for Huntington disease. Arch Neurol 54: 1353-1357
7. Folstein SE, Jensen B, Leigh RJ, Folstein MF (1983) The measurement of abnormal movement: methods developed for Huntington's disease. Neurobehav Toxicol Teratol 5: 605-609
8. Furtado S, Suchowersky O, Rewcastle B, Graham L, Klimek ML, Garber A (1996) Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol 39: 132-136
9. Garcia Ruiz PJ, Hernandez J, Cantarero S, Bartolome M, Sanchez BV, Garcia dY (2002) Bradykinesia in Huntington's disease. A prospective, follow-up study. J Neurol 249: 437-440
10. Kirkwood SC, Siemers E, Viken R, Hodes ME, Conneally PM, Christian JC, Foroud T (2002) Longitudinal personality changes among presymptomatic Huntington disease gene carriers. Neuropsychiatry Neuropsychol Behav Neurol 15: 192-197
11. Lalonde R, Botez-Marquard T (1997) The neurobiological basis of movement initiation. Rev Neurosci 8: 35-54
12. Lawrence AD, Weeks RA, Brooks DJ, Andrews TC, Watkins LH, Harding AE, Robbins TW, Sahakian BJ (1998) The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain 121 (Pt 7): 1343-1355
13. Müller T, Schäfer S, Kuhn W, Przuntek H (2000) Correlation between tapping and inserting of pegs in Parkinson's disease. Can J Neurol Sci 27: 311-315
14. Müller T, Kuhn W, Schulte T, Przuntek H (2003) Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease. Neurosci Lett 339: 25-28
15. Nieoullon A (2002) Dopamine and the regulation of cognition and attention. Prog Neurobiol 67: 53-83
16. Pal PK, Lee CS, Samii A, Schulzer M, Stoessl AJ, Mak EK, Wudel J, Dobko T, Tsui JK (2001) Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET. Parkinsonism Rel Disord 7: 305-309
17. Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I (2001) Clinical markers of early disease in persons near onset of Huntington's disease. Neurology 57: 658-662
18. Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 41: 689-692
19. Phillips JG, Bradshaw JL, Chiu E, Teasdale N, Iansek R, Bradshaw JA (1996) Bradykinesia and movement precision in Huntington's disease. Neuropsychologia 34: 1241-1245
20. Redondo VL, Brown RG, Chacon P Jr (2001) [Executive dysfunction in Huntington's disease]. Rev Neurol 32: 923-929
21. Reilmann R, Kirsten F, Quinn L, Henningsen H, Marder K, Gordon AM (2001) Objective assessment of progression in Huntington's disease: a 3-year follow-up study. Neurology 57: 920-924
22. Rubin AJ, King WM, Reinbold KA, Shoulson I (1993) Quantitative longitudinal assessment of saccades in Huntington's disease. J Clin Neuroophthalmol 13: 59-66
23. Sanchez-Pernaute R, Kunig G, del Barrio AA, de Yebenes JG, Vontobel P, Leenders KL (2000) Bradykinesia in early Huntington's disease. Neurology 54: 119-125
24. Thaut MH, Miltner R, Lange HW, Hurt CP, Hoemberg V (1999) Velocity modulation and rhythmic synchronization of gait in Huntington's disease. Mov Disord 14: 808-819
25. van Vugt JP, Siesling S, Piet KK, Zwinderman AH, Middelkoop HA, van Hilten JJ, Roos RA (2001) Quantitative assessment of daytime motor activity provides a responsive measure of functional decline in patients with Huntington's disease. Mov Disord 16: 481-488